Specific and limited radiopharmaceuticals can be devised and produced based on the genetic categorization of BC, which can be divided into basal-like, luminal (A/B), HER2, and breast-like subtypes according to patient prognosis [49]. The gene discussed is ERBB2; the disease is breast cancer.